Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

Chiesi’s rare disorder therapies approved by SMC for Fabry disease and epidermolysis bullosa

Rare diseases currently affect around 436,000 people living in Scotland

- PMLiVE

uniQure’s investigational gene therapy shown to slow Huntington’s disease progression

The neurodegenerative disorder affects approximately 70,000 people in Europe and the US

- PMLiVE

Francis Crick Institute appoints Edith Heard as new director and chief executive

The current director-general of the European Molecular Biology Laboratory will take on the role next year

- PMLiVE

AstraZeneca selects WPP as primary network for global oncology business

A bespoke WPP team will bring together experts from the organisation's global network

- PMLiVE

Ipsen gains global rights to Foreseen’s ADC candidate in deal worth up to $1.03bn

FS001 is currently completing the final stages of preclinical development

- PMLiVE

Almirall announces NICE recommendation for Ebglyss in atopic dermatitis

The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK

- PMLiVE

WHO publishes guidance for HPV vaccine developers to help tackle cervical cancer

In more than nine out of ten cases, the HPV virus leads to cervical cancer, the fourth most common cancer in women globally

- PMLiVE

Hologic survey reveals major screening action gap in millions of US women

An estimated 72 million women in the US have skipped or delayed recommended preventative screening

- PMLiVE

Oxford PharmaGenesis welcomes Christopher Rains on board as our first Non-Executive Director

Oxford PharmaGenesis is proud to announce the appointment of Christopher Rains as our first Non-Executive Director, strengthening the Board with over 30 years of experience in the pharmaceutical industry. A...

Oxford PharmaGenesis

- PMLiVE

FDA approves Arcutis’ Zoryve cream to treat mild-to-moderate atopic dermatitis

Approximately 16.5 million adults and 9.6 million children in the US are affected by the inflammatory skin condition

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by SMC for advanced melanoma

The fifth-most common cancer in the UK affects more than 1,200 people in Scotland every year

- PMLiVE

Sanofi/Regeneron’s Dupixent shows significant improvements in paediatric eosinophilic oesophagitis

The chronic inflammatory disease affects approximately one in 2,000 people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links